Incyte | INCY - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agenus USD 95.28M 38.15M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Exelixis USD 1.21B 234.65M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Incyte USD 6.03B 542.31M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
MacroGenics USD 182.52M 37.42M 2026-03
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 27.35B 744M 2026-06
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03